1.. Introduction {#S5}
================

Neurodegenerative changes, eventually leading to dementia due to Alzheimer's disease (AD), begin to accumulate approximately 20 years before clinical symptoms appear \[[@R1]\]. With the lack of curative treatment for dementia due to AD, research is moving toward the prodromal and preclinical stages of AD \[[@R2]\]. Subjective cognitive decline (SCD) refers to the subjective experience of cognitive decline, without objective impairment on cognitive assessment \[[@R3]\]. Compared to individuals without SCD, cognitively normal elderly subjects experiencing complaints have an increased risk of subsequent objective cognitive decline, that is, progression to mild cognitive impairment (MCI) and dementia \[[@R4]--[@R9]\]. Therefore, SCD has been suggested to be a possible first symptomatic expression of preclinical AD \[[@R2],[@R3]\].

The conceptual framework on SCD published by the international Working Group (SCD-I) has a focus on SCD as an early harbinger of AD, proposing the SCD-plus criteria as potential risk factors for preclinical AD \[[@R3]\]. However, SCD may also precede other dementia subtypes with a gradual onset, such as vascular dementia (VaD), dementia with Lewy Bodies (DLBs), or frontotemporal dementia (FTD). Although individuals with SCD have an increased risk of dementia \[[@R4]--[@R9]\], the incidence rate of progression from SCD to AD dementia, and especially to non-AD dementia, has not been estimated before.

For cognitively normal individuals, risk factors of dementia include higher age, lower education, and apolipoprotein E (*APOE*) ε4 status \[[@R10],[@R11]\]. Whether these risk factors influence the risk of progression to AD and non-AD types of dementia in patients with SCD in a similar way remains to be further investigated. The aim of our multicenter study including both memory clinic and community-based cohorts of SCD was to estimate incidence rates of dementia, both for AD and non-AD.

2.. Methods {#S6}
===========

This collaborative project was initiated during a public meeting of the Subjective Cognitive Decline Professional Interest Area during the Alzheimer's Association International Conference in 2015, which was facilitated by the International Society to Advance Alzheimer's Research and Treatment.

2.1.. Setting and recruitment {#S7}
-----------------------------

Eleven cohorts provided data, see [Table 1](#T1){ref-type="table"} for an overview of participating cohorts and the number of subjects included. Across studies, there are differences in operationalization of SCD. We deliberately took the case definition of each study as the starting point; [Table 1](#T1){ref-type="table"} provides information on center-specific operationalization of SCD. Cohorts were defined as memory clinic setting when patients were referred to the memory clinic by a physician, or actively approached the respective center for evaluation. Cohorts were labeled as community setting when the study was population based, for example, if recruitment was organized via standardized evaluation of eligible participants in a predefined district or when participants were recruited by active (media) appeal.

2.2.. Participants {#S8}
------------------

We included SCD participants in the analysis if (1) the participant reported subjective experience of cognitive decline on one or more cognitive domains; (2) the participant had normal baseline cognition, defined by results of cognitive assessment within normal ranges (center-specific), and criteria for MCI or any dementia were not met \[[@R12]--[@R15]\], and (3) had at least one follow-up assessment (\>8 months from baseline) with repeated evaluation of diagnosis. Controls were provided by the same cohorts but did not endorse inclusion criterion (1). Exclusion criteria were MCI, dementia, alcohol or substance abuse, or any psychiatric or neurological disease possibly causing memory complaints (i.e. epilepsy, Parkinson's disease). In sum, 11 cohorts provided 5521 participants; 2978 cases with SCD and 1391 controls without SCD, see [Fig. 1](#F1){ref-type="fig"} for an overview of participant selection.

2.3.. Outcome measure {#S9}
---------------------

The main outcome measure was progression to dementia. Definitions and criteria of specific dementia used in each cohort are provided in the supplement or study design reports. Besides dementia due to AD \[[@R13],[@R16]\], we evaluated the following non-AD dementia: VaD \[[@R17]\], FTD \[[@R14]\], and DLBs \[[@R15]\]. Other less frequent neurodegenerative causes of dementia, such as corticobasal syndrome or progressive supranuclear palsy, were classified as "dementia other."

2.4.. Demographic features of the study population {#S10}
--------------------------------------------------

Sociodemographic features and cognition were assessed in each cohort. Here, we report on age, sex, education, global cognition, and *APOE* ε4 carrier status. Information on years of education was available for 2142 (71.9%) participants. Cognitive function was screened with the Mini-Mental State Examination (MMSE) \[[@R18]\] and available for 2928 (98.3%) participants. APOE genotyping was performed according to local procedures and available for 2417 (81.2%) participants. We dichotomized *APOE* ε4 status (0 ε4 alleles vs. 1 or 2 ε4 alleles).

2.5.. Statistical analyses {#S11}
--------------------------

Data were analyzed using SPSS (version 22; IBM, Armonk, NY, USA) and Stata 15 (Stata Statistical Software: Release 15, StataCorp LP). We evaluated baseline characteristics and assessed differences between memory clinics and community cohorts using linear mixed models (continuous variables) or generalized estimating equations (dichotomous variables), taking into account random center effects.

We calculated incidence rates of dementia per 1000 person-years with accompanying 95% Poisson confidence intervals and incidence rates of AD and non-AD dementia separately.

We studied the effect of age, sex, MMSE, number of education years, *APOE* ε4 carrier status, and recruitment setting (memory clinic vs. community cohort) on the risk of dementia by using shared-frailty Cox proportional hazards models, taking into account within-group center effects. We conducted simple and multiple Cox regression models and accounted for residual variation in progression risk among studies by including a center-specific random effect. To evaluate whether effects of MMSE and education were generalizable between centers, we added mean MMSE and mean number of education years per center as variables. Finally, we added interaction effects of recruitment setting and variables age, sex, MMSE, and number of education years. We repeated the analyses stratified for AD and non-AD dementia.

For visualization, we constructed Kaplan-Meier curves of progression to dementia in general and for dementia due to AD and to non-AD per decade of age. When calculating the risk of AD, cases progressing to non-AD dementia were censored and vice versa. *P* \< .05 was considered to be significant.

3.. Results {#S12}
===========

3.1.. Demographics {#S13}
------------------

[Table 2](#T2){ref-type="table"} shows the baseline demographic features of the study population. Individuals with SCD in memory clinic cohorts were on average 10 years younger, and they were less often females, had more years of education, and were more often *APOE* ε4 positive than individuals with SCD in community-based cohorts and controls. Adjusted for random center effects, MMSE scores were lower in controls than in individuals with SCD. For all variables, individuals with SCD from the community were intermediate between SCD from a memory clinic and controls. Center characteristics are provided in [Supplementary Table](#SD1){ref-type="supplementary-material"}.

3.2.. Progression to AD and non-AD dementia {#S14}
-------------------------------------------

During follow-up, 3.9 ± 2.2 years (range 0.9--12.8 years), 84 (6% of 1391) controls without SCD progressed to dementia, of which 61 (66% of demented) to AD and 23 (33% of demented) and non-AD. Among individuals with SCD, 194 (7% of 2978) progressed to dementia, attributed to AD for 127 (65% of demented) or another type of dementia for 67 (35%). Within the non-AD dementia cohort, 30 (16% of all dementia cases) individuals with SCD progressed to VaD, 8 (4%) progressed to frontotemporal lobar degeneration (FTLD), 9 (5%) to DLB, and 20 (10%) to another type of non-AD dementia. [Fig. 2](#F2){ref-type="fig"} shows the percentages of dementia diagnoses in community cohorts and memory clinics. In a multilevel model, we compared percentages of dementia diagnoses in community and memory clinic cohorts and found that individuals with SCD in community-based cohorts more often received a diagnosis of VaD (23% community vs. 9% memory clinic \[P = .01\]). By contrast, diagnoses of DLB and FTLD were more frequently made in a memory clinic setting (DLB 8% memory clinic vs. 1% community (P = .070); FTLD: 8% memory clinic versus 0% community, model did not converge). The percentage of a diagnosis of AD did not differ between recruitment settings (67% vs. 63%, *P* = .55), \\ nor did the number of cases with "dementia other" (memory clinic 8% vs. community cohort 13% \[P = .34\]).

3.3.. Incidence rate of dementia {#S15}
--------------------------------

Among individuals with SCD, the incidence rate of dementia was 17.7 (95% Poisson confidence interval 15.2--20.3) per 1000 person-years. The incidence rate per 1000 person-years for dementia due to AD was 11.5 (9.6--13.7) and for non-AD dementia 6.1 (4.7--7.7). In controls without SCD, the incidence rate of dementia was 14.2 (11.3--17.6); 10.1 (7.7--13.0) for AD and 4.1 (2.6--6.0) for non-AD. [Table 3](#T3){ref-type="table"} shows the incidence rates of dementia in memory clinics (20.0 \[16.4--24.1\]) and community cohorts (15.4 \[12.3--19.0\]) per decade and for AD and non-AD dementia separately. Incidence rates increased with age, as visualized in [Figs. 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}. Multivariate Cox proportional hazards models showed that compared to controls without SCD, individuals with SCD in memory clinic cohorts are at a clearly increased risk of dementia ([Table 4](#T4){ref-type="table"}). The increased risk of dementia in community-based cohorts did not reach significance. In addition, higher age, lower MMSE, and *APOE* ε4 carrier status were independent predictors of incident dementia. We evaluated center random effects for MMSE and education in the Cox proportional hazards models, which did not specifically alter results, concluding that findings were generalizable for MMSE and education.

Stratified for AD or non-AD outcomes, the increased risk of dementia in individuals with SCD was particularly attributable to incident non-AD dementia. Lower MMSE increased the risk of both AD and non-AD dementia ([Table 4](#T4){ref-type="table"}), while higher age was associated with an increased risk of non-AD dementia. There was no significant effect of sex, education, or APOE in the stratified analyses.

4.. Discussion {#S16}
==============

In this multicenter study including both memory clinic and community-based cohorts of SCD, we evaluated incidence rates of dementia, both for AD and non-AD. We found an overall dementia incidence rate in individuals with SCD of 17.7 per 1000 person-years, compared to 14.2 in controls without SCD. Particularly, in memory clinic patients with SCD, the risk of non-AD dementia is strongly increased. In line with incidence studies of dementia subtypes \[[@R19],[@R20]\], roughly one of 3 incident dementia in individuals with SCD cases was due to non-AD. Of note, non-AD dementia in memory clinics often comprised FTD or DLB, while in community-based cohorts, VaD was relatively more common. Other determinants of incident dementia included higher age, lower baseline cognition, and *APOE* ε4 carriership.

Our data clearly showed that recruitment setting modifies the risk of progression from SCD to dementia. It is well known that recruitment setting (i.e. memory clinic vs. community) affects studies in SCD \[[@R3],[@R21],[@R22]\]. However, the number of studies directly comparing recruitment setting is small \[[@R9],[@R23]--[@R25]\]. A previous meta-analysis suggested that the annual conversion rate from SCD to dementia did not differ between memory clinics and community cohorts \[[@R9]\], and likewise at first sight, our memory clinic cohorts also had only slightly higher incidence rates (20.1/1000 person-years) compared with community cohorts (15.4/1000 person-years). However, heterogeneity between studies has repeatedly been mentioned in SCD studies \[[@R9],[@R21]\], and a recent study showed that progression to MCI is more common in individuals with SCD recruited at a memory clinic than in a community-based setting \[[@R26]\]. We also observed great heterogeneity between cohorts in study design, center, and patient characteristics, and to allow meaningful pooling of data, we used a multilevel statistical approach, carefully taking into account center differences. Particularly, memory clinic cohorts were on average a decade younger, explaining their overall lower incidence. When we stratified by age, our data revealed that in every age bin, incidence of dementia is higher in the memory clinic than in the community-based cohorts of individuals with SCD. The only exception was the oldest age bin \>90 years, where data in memory clinics were simply lacking, and the incidence of dementia in community-based cohorts was high. Our data illustrate that memory clinic patients who actively seek help for their perceived cognitive problems, indeed, are more likely to experience the first (preclinical) signs of a neurodegenerative disease \[[@R23],[@R24]\].

Our findings provide evidence that SCD is not only a potential harbinger of AD but also of other dementia. Two-third of incident dementia in individuals with SCD was attributable to AD dementia, whereas approximately one-third was attributable to another type of dementia. The relative frequencies of individuals with SCD progressing to FTLD, DLB, and VaD seemed comparable with previous dementia incidence studies \[[@R19],[@R20],[@R27]--[@R29]\]. In memory clinic cohorts, DLB and FTLD were more frequently diagnosed than in community cohorts. By contrast, VaD was more often diagnosed in the older community cohort individuals with SCD. This difference could be a reflection of differing operationalization of diagnostic criteria for dementia, which may be handled differently between settings \[[@R30]\], for example, VaD in memory clinic settings often requires neuroimaging criteria, whereas in community-based settings such a diagnosis may be based on clinical presentation only. Diagnosis of DLB or FTLD requires careful neurological examination by an expert neurologist, available mostly in specialized clinics rather than in community settings. Also, individuals with early VaD or DLB might be referred for evaluation to general neurology, instead of a memory clinic, as patients complain rather of neurological symptoms, such as parkinsonism or gait change, than memory decline. Furthermore, individuals with FTLD may be less likely to participate in voluntary studies because of disease characteristics \[[@R31]\].

The large majority of individuals with SCD in both memory clinic and community-based cohorts did not progress to any type of dementia, but rather remained cognitively normal. Despite the growing interest in SCD as a putative first syndrome stage of AD, the group of individuals seeking help where a neurodegenerative disorder can be excluded as cause of their problems also merits our attention. From studies in the field of MCI and early studies in SCD, it is clear that, for example, cerebrospinal fluid biomarkers have particularly good negative predictive value, illustrating that their optimal clinical use is for reassurance of individuals with normal biomarkers \[[@R32],[@R33]\]. Alternative causes of SCD could be subclinical psychiatric disorders, personality traits, or surmenage. Individuals with SCD who are unlikely to progress to AD or non-AD dementia could be reassured and might benefit from counseling and/or lifestyle interventions, aiming to promote a healthy brain.

We evaluated which determinants contributed to an increased risk of progression from SCD to dementia and found that higher age, lower baseline MMSE, *APOE* ε4 status, and recruitment setting resulted in an increased risk of dementia, which is consistent with the literature \[[@R9],[@R34],[@R35]\]. We found that higher age contributed relatively more to the risk of AD than non-AD dementia in individuals with SCD. A possible explanation could lie in the fact that some non-AD dementia, such as FTLD, are relatively more often diagnosed at a younger age, thus reflecting less contribution of a higher chronologic age in the risk of non-AD dementia in comparison with AD dementia \[[@R31]\]. The effect of MMSE on the risk of clinical progression also seemed stronger for AD than for non-AD. The MMSE is mainly designed as a global cognitive screening tool and most sensitive for disturbances in memory and orientation \[[@R18]\]. Because the memory domain is relatively less affected in non-AD dementia, it is conceivable that MMSE is less sensitive for non-AD dementia \[[@R36]\]. *APOE* ε4 status was associated with an increased risk of dementia, which appeared to be attributable to the risk of AD but not to non-AD, which is in agreement with the literature \[[@R37],[@R38]\].

The limitations of the study include the substantial heterogeneity in cohort characteristics. The heterogeneity includes differences in demographics of participants among centers and substantial inherent center characteristics such as the definition of SCD, the administered SCD questionnaires, the use of (magnetic resonance imaging, positron emission tomography, or cerebrospinal fluid) bio­markers in the diagnostic process, and the outcome measures (differences in dementia criteria used). Furthermore, recruitment setting has been shown to be a moderator of SCD results, as discussed previously. Nonetheless, we were able to combine these cohorts by using a multilevel statistical approach, using shared-frailty Cox models and taking into account random center effects. Our results underline the importance of the harmonized research criteria for SCD, which have been put forward by the SCD-I working group \[[@R3],[@R39]\]. In this study, we had no information available on different domains of cognitive complaints, such as memory domains versus nonmemory domains. As one-third of dementia diagnoses were non-AD, evaluation of SCD in nonmemory domains using questionnaires and also qualitative assessment is of interest to better understand the underlying pathology of SCD \[[@R40]\]. Also, we had no comprehensive cognitive test battery or biomarker data available for a large part of our cohort, and we cannot exclude the possibility of misdiagnosis in a number of cases. Future studies should include a wider range of cognitive tests and biomarkers to further evaluate the process of differentiating between AD and non-AD types of dementia. We did not take into account all available SCD cohorts, but this collaborative study did originate from the International Society to Advance Alzheimer's Research and Treatment's SCD Professional Interest Area, including all centers that wanted to contribute data. The strengths of the study, therefore, include the large sample of SCD patients, with participating centers from around the world. Furthermore, this is the first time that the incidence of non-AD dementia is evaluated in the context of SCD.

Members of the international SCD Working Group (SCD-I) have published a conceptual framework on SCD research to facilitate harmonization of SCD research \[[@R3],[@R39]\]. The framework, however, is focused on the detection of preclinical AD and not so much on the preclinical stages of other dementia. The risk of preclinical AD has been suggested to be specifically modified by self-reported memory decline \[[@R7]\], and a large overview of SCD measures indicated that most instruments indeed evaluate memory-specific decline \[[@R3],[@R21]\]. However, as approximately one-third of progressing patients in our SCD sample progressed to another type of dementia than AD, the importance of nonmemory characteristics needs to be considered when evaluating SCD.
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###### 

Overview of participating centers and their characteristics

  Center                                                                                                                                               Setting                                                Definition of SCD                                                                                           Follow-up information   N, total   N, SCD   N, controls
  ----------------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------- ----------------------- ---------- -------- -------------
  Alzheimer Disease Neuroimaging Initiative (ADNI) and Indiana Alzheimer Disease Center \[[@R41],[@R42]\]     USA                                      Memory clinic; multicenter with standardized methods   Normal cognition 1 MC visit because of complaints (assessed by CCI)                                         Annual FU               372        126      246
  Australian Imaging, Biomarkers and Lifestyle Study (AIBL) \[[@R43]\]                                        Australia                                Community; multicenter with standardized methods       Normal cognition 1 cognitive complaints question (Mac-Q): Yes                                               FU interval 18 months   1636       491      161
  Amsterdam Dementia Cohort \[[@R44]--[@R46]\]                                                                The Netherlands                          Memory clinic; single-center                           Normal cognition 1 MC visit because of complaints                                                           Annual FU               463        463      0
  Barcelona Hospital Clinic i Universitari                                                                    Spain                                    Memory clinic; single-center                           Normal cognition 1 MC visit because of complaints                                                           Annual FU               75         52       23
  German Dementia Competence Network (DCN) \[[@R47]\]                                                         Germany                                  Memory clinic; multiple singlecenter studies           Normal cognition 1 MC visit because of complaints Participant did not meet Jak- Bondi criteria \[[@R48]\]   Annual FU               256        256      0
  Development of Screening Guidelines and Clinical Criteria for Pre-dementia AD study (DESCRIPA) \[[@R49]\]   Europe[\*](#TFN3){ref-type="table-fn"}   Memory clinic; multiple singlecenter studies           Normal cognition 1 MC visit because of complaints                                                           Annual FU               245        224      0
  Hellenic Longitudinal Investigation of Aging and Diet (HELIAD) \[[@R50]\]                                   Greece                                   Community; single-center                               Normal cognition 1 cognitive complaints questionnaire: Yes                                                  Annual FU               531        154      309
  INSIGHT pre-AD study, Paris \[[@R51],[@R52]\]                                                               France                                   Community; single-center                               Normal cognition 1 cognitive complaints questionnaire: Yes                                                  FU after 3 years        318        318      0
  Leipzig Longitudinal Study of the Aged (LEILA751) \[[@R53]\]                                                Germany                                  Community; single-center                               Normal cognition 1 cognitive complaints questionnaire: Yes                                                  FU interval 18 months   670        169      501
  Sydney Memory and Ageing Study (MAS) \[[@R54]\]                                                             Australia                                Community; single-center                               Normal cognition 1 cognitive complaints question: Yes                                                       FU interval 24 months   467        316      151
  New York University Langone Medical Center (NYU)                                                            USA                                      Memory clinic; single-center                           Normal cognition 1 MC visit because of complaints                                                           Annual FU               488        409      0

Abbreviations: CCI, Cognitive Change Index; FU, follow-up; MC, memory clinic; SCD, subjective cognitive decline.

NOTE: Of the participating cohorts, there were eight single-center studies, two multicenter studies with standardized methods (ADNI and AIBL), and two cohorts composed of data from multiple single-center studies (DCN Germany and DESCRIPA). ADNI and the single site Indiana ADC cohort were combined as both were assessed and included based on the CCI.

To prevent possible overlap of participants, all cases from the VU Medical Center included in the DESCRIPA data set were not included in analyses (n = 22). See [Supplementary Table](#SD1){ref-type="supplementary-material"} for more information.

###### 

Baseline demographic features of study participants (N = 4369)

                                                       All          Controls     Community    Memory clinic   
  ---------------------------------------------------- ------------ ------------ ------------ --------------- --------------------------------------
  Number of cohorts                                                 6            5            6               
  Age, year                                            73 ± 9       77 ± 7       76 ± 6       67 ± 9          .000
  Female gender                                        2611 (60%)   889 (64%)    901 (62%)    821 (54%)       .000
  MMSE                                                 28.3 ± 1.7   27.9 ± 1.9   28.4 ± 1.4   28.4 ± 1.6      .000[\*](#TFN5){ref-type="table-fn"}
  Education, year^[†](#TFN6){ref-type="table-fn"}^     12 ± 4       11 ± 5       10 ± 4       14 ± 4          .000
  *APOE* e4 carrier^[‡](#TFN7){ref-type="table-fn"}^   888 (28%)    184 (26%)    261 (22%)    443 (36%)       .000
  Follow-up, year                                      3.9 ± 2.2    4.3 ± 2.0    3.9 ± 2.0    3.5 ± 2.3       .000

NOTE: Values are displayed as unadjusted mean ± standard deviation (SD) or N (%). Differences between memory clinic and community cohorts were assessed using linear mixed models (continuous variables) or generalized estimating equations (dichotomous variables) taking into account center random effects.

When taking into account center random effects, MMSE is lower in controls versus community cohorts versus memory clinic cohorts (P \< .001), whereas unadjusted means are shown in the table.

Data available for 77% (memory clinic 98%, community 44%, controls 88%).

Data available for 72% (availability memory clinic 82%, community 81%, controls 51%).

###### 

Incidence rates of dementia in general, and dementia due to AD and non-AD

                             Number of person years   Incidence rate/1000 person-years (95% Poisson confidence intervals)                      
  -------------------------- ------------------------ --------------------------------------------------------------------- ------------------ ----------------
  Controls (n = 1391)                                                                                                                          
   All                                                14.2 (11.3--17.6)                                                     10.1 (7.7--13.0)   4.1 (2.6--6.0)
   Age category                                                                                                                                
   \<60                      55                       0                                                                     0                  0
   60--70                    859                      2 (0--8)                                                              2 (0--8)           0
   70--80                    3379                     7(5--11)                                                              4 (2--7)           3 (2--6)
   80--90                    1547                     33 (25--43)                                                           25 (18--34)        8 (4--14)
   \>90                      81                       74 (27--161)                                                          62 (20--144)       12 (0--69)
  Community (n = 1448)                                                                                                                         
   All                       5647                     15.4 (12.3--19.0)                                                     9.7 (7.3--12.7)    5.7 (3.9--8.0)
   Age category                                                                                                                                
   \<60                      12                       0                                                                     0                  0
   60--70                    904                      2 (0--8)                                                              2 (0--8)           0
   70--80                    3222                     11 (8--15)                                                            6 (4--9)           5 (3--8)
   80--90                    1509                     32 (24--42)                                                           23 (16--32)        9 (5--16)
   \>90                      47                       60(12--175)                                                           20(1--111)         40 (5--145)
  Memory clinic (n = 1530)                                                                                                                     
   All                       5355                     20.1 (16.4--24.1)                                                     13.4(10.5--16.9)   6.5 (4.6--9.1)
   Age category                                                                                                                                
   \<60                      1271                     6 (2--11)                                                             2 (0--6)           4 (1--9)
   60--70                    1952                     17 (12--24)                                                           11 (7--16)         6 (3--11)
   70--80                    1571                     32 (24--42)                                                           22 (15--30)        10 (6--16)
   80--90                    447                      26 (20--58)                                                           31 (17--52)        4(1--15)
   \>90                      12                       0                                                                     0                  0

Abbreviation: AD, Alzheimer's disease.

NOTE: Results are displayed as incidence rates (95% Poisson confidence interval) per 1000 person-years. Analyses stratified for AD and non-AD types of dementia, age category, and recruitment setting.

###### 

Associations between determinants and the risk of dementia in general and dementia due to AD and non-AD in a combined SCD sample (n = 4369)

                                                       Dementia           AD                 Non-AD                                                    
  ---------------------------------------------------- ------------------ ------------------ ----------------- ------------------- ------------------- -------------------
  Controls                                             ref                ref                ref               ref                 ref                 ref
  SCD---community                                      2.1 (0.6--7.7)     1.5 (0.4--5.8)     1.8 (0.8--4.1)    0.7 (0.3--1.9)      4.6 (1.1--19.0)     2.2 (0.5--9.7)
  SCD---memory clinic                                  10.0 (2.9--34.0)   10.4 (3.4--32.0)   1.7 (0.8--3.6)    2.0 (1.0--4.1)      12.7 (3.1--51.4)    7.1 (1.8--27.3)
  Age, years                                           1.1 (1.1--1.1)     1.1 (1.1--1.1)     1.0 (1.0--1.0)    1.0 (1.0--1.0)      1.09 (1.05--1.12)   1.07 (1.02--1.11)
  Female gender                                        1.1 (0.9--1.4)     1.0 (0.7--1.5)     1.0 (0.9--1.04)   1.0 (0.9--1.1)      0.8 (0.5--1.3)      0.6 (0.3--1.0)
  MMSE^[h](#TFN12){ref-type="table-fn"}^                                  0.7 (0.65--0.8)                      0.95 (0.92--0.98)                       0.8 (0.7--0.9)
  Education, years[\*](#TFN13){ref-type="table-fn"}                       1.0 (0.97--1.1)                      1.0 (0.98--1.01)                        1.0 (0.9--1.1)
  *APOE* ε4 status^[†](#TFN14){ref-type="table-fn"}^                      1.8 (1.3--2.5)                       1.0 (0.9--1.1)                          1.1 (0.6--2.1)

Abbreviations: AD, Alzheimer's disease; SCD, subjective cognitive decline.

NOTE: Results are presented as hazard ratios (95% confidence interval) and reflect the risk of progression from SCD to dementia in general and dementia due to AD and non-AD. Model 1: age and gender adjusted. Model 2; additionally adjusted for MMSE, education in years, and *APOE* ε4 status (due to missing data in MMSE, education, and APOE, model 2 has less observations). HRs were calculated per determinant in univariate models and combined in multivariate models.

Higher scores reflect better performance.

Data available for 77%.

Data available for 72%.

###### RESEARCH IN CONTEXT

1.  Systematic review: We evaluated literature on incidence numbers of subjective cognitive decline (SCD) and risk factors of progression from SCD to dementia, with a particular focus on both AD and non-AD types of dementia.

2.  Interpretation: This large collaborative study including 2978 participants with SCD, indicated that SCD is a prodrome of both AD and non-AD dementia. Risk factors for progression from SCD to dementia included higher age, lower MMSE, apolipoprotein E, and recruitment setting, specifically memory clinic setting.

3.  Future directions: As we evaluated risk factors for progression from SCD to dementia, we concluded that these risk factors, in particular recruitment setting, should be taken into account while interpreting and comparing future study results. Future studies may include biomarker data while assessing risk factors of progression from SCD to dementia.
